
usd oct pm et
summari develop small molecul therapeut treatment wide rang diseas led
cystic fibrosi anti-inflammatori condit
price-to-earnings oper ep
risk assess reflect view vertex
reliant expand cystic fibrosi cf franchis
wider patient sub-group see clear
domin leader market
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
expect sale grow
approxim billion grow
sale tie
cystic fibrosi cf treatment sale
rose billion compris
revenu wherea cf sale compris
revenu expect cf
product revenu grow year-over-year
billion driven nearli
growth sale symdeko
launch earli sale
matur product kalydeco orkambi
execut manag
issu past year decemb
cfo month resign slightli
month later januari
interim cfo also
termin found sudden execut
departur concern
regard capit alloc expect
focu extern innov
strategi involv activ licens
collabor like look
opportun expand cystic fibrosi
franchis set technolog tool
earli mid-stag pipelin asset
think recent share price mostli
captur valu grow base
busi cystic fibrosi cf think
investor underestim upsid potenti
early- mid-stag clinic program
outsid cf grow exposur
diseas beta thalassemia late octob
tripl combin therapi
tezacaftor ivacaftor trikafta
cf approv fda three
month five month ahead origin
market opportun
cf popul estim
patient cf patient
current estim elig
risk opinion target price includ
failur expand cf franchis
failur poor execut new product
target
start ep
compar rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview biotechnolog compani focus
develop commerci therapi treatment cystic fibrosi cf compani also
advanc research develop area includ pain sickl cell diseas beta-thalassemia
antitrypsin defici vrtx program crispr develop clinic candid
sickl cell diseas beta-thalassemia uniqu one first human trial
use power gene-edit technolog
market background cf life shorten genet diseas affect approxim peopl
north america europ australia cf caus defect miss cftr protein result
mutat cftr gene absenc work cftr protein result poor flow salt water
cell number organ includ lung result thick sticki mucu build
block passag mani organ lead varieti symptom particular mucu build
clog airway lung caus chronic lung infect progress lung damag
vrtx commerci medicin symdeko/symkevi orkambi kalydeco collect approv
treat approxim half cf patient north america europ australia believ
in-develop tripl combin regimen treatment could address cf
patient current treatabl multipl tripl combin program
phase develop expect submit least one tripl combin therapi
commerci approv
competit dynam number compani seek identifi develop drug candid
treatment cf includ public compani proqr
therapeut proteostasi therapeut well sever privat compani although
first compani success develop medicin treat underli caus cf
product collect approv treat portion patient cf futur treatment regimen
includ vrtx tripl combin regimen could deliv enhanc benefit patient
current treat vrtx medicin
impact major develop late octob vrtx tripl combin therapi
tezacaftor ivacaftor trikafta cf approv fda three month five month
ahead origin expect drug significantli expand market opportun
cf popul estim patient cf patient
current estim elig treatment largest develop prior tripl
combin therapi launch symdeko
juli receiv first fda approv orkambi treat underli caus cystic
fibrosi patient older mutat approv signific mileston
enabl becom clear market leader treatment cf
subsequ obtain addit approv orkambi treat addit subset cf patient
financi trend year end decemb achiev revenu billion
year-over-year reflect compound annual growth rate compani
adjust ep prior-year gener grow level
posit free cash past three year gener maintain signific net cash posit
believ substanti financi flexibl easili fund oper
execut vice-president chief
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
measur taken legisl regulatori
bodi lower drug price
democrat appear motiv
address drug price still think
suffici bipartisan impetu effect
signific chang near futur
anoth sourc price pressur drug
manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price especi sinc
major pbm merg major insur
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
fda-approv biosimilar
manufactur aggress use patent
law commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
year-to-d septemb
compar rise valu
 composit index
declin
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newli approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
recent year mega-d
announc bristol-my
squibb acquisit celgen
celg acquisit
botox manufactur allergan matur
biopharmaceut firm look off-set
lost revenu expir patent fail
ventur promis late-stag pipelin
addit exampl think gilead
scienc could
interest larg collabor
agreement biotechnolog compani
low debt level attract valuat
rel industri make
think investor interest biotechnolog
stock mute recent high drug
price come heighten scrutini
 polit apparatu last
year despit talk lower drug
price seen particularli sever
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
averag ep ep vs
higher estim maintain ep estim initi
ep revenu increas million driven us
launch symdeko sale includ million symdeko us
regard capit alloc expect focu extern innov
strategi involv activ licens collabor like
look opportun expand cystic fibrosi franchis set technolog
tool earli mid-stag pipelin asset exampl
research develop therapi sickl cell diseas pain patient
small fiber neuropathi beta-thalessemia provid detail
departur two cfo past sever month continu view
uncertainti signific risk /kevin huang cfa
et cfra lower opinion share hold
buy maintain target price
lower opinion share hold see increas risk
near-term share price perform what-appears-to-b c-suit
yesterday termin interim cfo ian smith also
compani person behavior violat vertex code
conduct valu last month then-cfo thoma graney
announc immedi resign cfo view departur two cfo
within less two month red flag addit delay
announc earn call year consist
announc first week januari past four year concern
event may indic issu compani
could innocu explan impact compani valu
see increas near-term risk due uncertainti /kevin huang cfa
analyst research note compani news
pm et cfra reiter buy opinion share
increas price target reflect
ratio start ep estim
therapi trikafta approv fda three month
five month ahead expect announc grant
nation reimburs spain orkambi symkevi follow
reimburs approv australia symdeko orkambi two day earlier
encourag earli approv trikafta
provid enhanc efficaci exist patient also allow
address untreat subset patient cystic fibrosi believ
well-posit meet suppli commerci organ demand
earlier-than-expect launch trikafta lift ep estim
ep /kevin huang cfa
pm et cfra rais opinion share inc
buy hold lift opinion share
becom less concern compani late earli
cfo departur still think chanc cfo
departur may relat account concern howev posit potenti
early- mid-stag stage clinic candid outweigh risk
opinion exampl research develop non-opioid base
pain therapi crispr-bas gene-edit capabl -- technolog
hold great promis success think current valuat mostli
captur valu compani cystic fibrosi franchis
assign much valu compani early- mid-stag pipelin addit
compani financi strong posit debt cash flow
perspect view favor especi given grow concern
et cfra maintain hold opinion share
inc rais target base ratio
ep ep vs surpass
consensu expect due strong commerci perform lift
ep estim ep
product revenu increas million driven continu
 launch symdeko sale symdeko/symkevi increas sequenti
million million last week submit new
drug applic tripl combin tezavaftor
ivacaftor fda look ahead expect acquir earli
stage asset complement compani pipelin certainli capabl
increas capit expenditur given compani robust balanc sheet
cash flow top hurri acquir develop asset
supplement growth unlik allow strateg
 /kevin huang cfa
pm et cfra maintain hold opinion share
lower target base ratio
ep reflect recent industry-wid
multipl compress adjust ep estim
ep ep vs higher
estim product revenu increas million driven
continu launch symdeko sale symdeko symkevi increas
sequenti million million
surpris quarter overal outlook mostli
unchang compani remain track submit new drug applic nda
one tripl combin medicin market
author applic europ welcom new
cfo charli wagner note clinic molecul treatment
antitrypsin defici receiv fast-track design
fda yesterday /kevin huang cfa
et cfra maintain hold opinion share
maintain target slightli
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
